Published online before print August 14, 2006, doi: 10.1161/CIRCULATIONAHA.106.612812
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
(Circulation. 2006;114:774-782.)
© 2006 American Heart Association, Inc.
Coronary Heart Disease |
Adverse Impact of Bleeding on Prognosis in Patients With Acute Coronary Syndromes
From the Thrombosis Service (J.W.E.) and Population Health Research Institute (J.W.E., S.R.M., S.S.A., C.X., S.Y.), Hamilton Health Sciences, Hamilton, Canada; Department of Medicine, McMaster University, Hamilton, Ontario, Canada (J.W.E., S.R.M., S.S.A., S.Y.); and University and the Royal Infirmary of Edinburgh, Edinburgh, Scotland, UK (K.A.A.F.).
Correspondence to John Eikelboom, Thrombosis Service, Hamilton General Hospital, 237 Barton St East, Hamilton, Ontario L8L 2X2, Canada. E-mail eikelbj{at}mcmaster.ca
Received January 7, 2006; revision received June 21, 2006; accepted June 22, 2006.
Background— The use of multiple antithrombotic drugs and aggressive invasive strategies has increased the risk of major bleeding in acute coronary syndrome (ACS) patients. It is not known to what extent bleeding determines clinical outcome.
Methods and Results— Using Cox proportional-hazards modeling, we examined the association between bleeding and death or ischemic events in 34 146 patients with ACS enrolled in the Organization to Assess Ischemic Syndromes and the Clopidogrel in Unstable Angina to Prevent Recurrent Events studies. Patients with major bleeding were older, more often had diabetes or a history of stroke, had a lower blood pressure and higher serum creatinine, more often had ST-segment changes on the presenting ECG, and had a 5-fold-higher incidence of death during the first 30 days (12.8% versus 2.5%; P<0.0001) and a 1.5-fold-higher incidence of death between 30 days and 6 months (4.6% versus 2.9%; P=0.002). Major bleeding was independently associated with an increased hazard of death during the first 30 days (hazard ratio, 5.37; 95% CI, 3.97 to 7.26; P<0.0001), but the hazard was much weaker after 30 days (hazard ratio, 1.54; 95% CI, 1.01 to 2.36; P=0.047). The association was consistent across subgroups according to cointerventions during hospitalization, and there was an increasing risk of death with increasing severity of bleeding (minor less than major less than life-threatening; P for trend=0.0009). A similar association was evident between major bleeding and ischemic events, including myocardial infarction and stroke.
Conclusions— In ACS patients without persistent ST-segment elevation, there is a strong, consistent, temporal, and dose-related association between bleeding and death. These data should lead to greater awareness of the prognostic importance of bleeding in ACS and should prompt evaluation of strategies to reduce bleeding and thereby improve clinical outcomes.
CLINICAL PERSPECTIVE
Related Article:
-
Issue Highlights
Circulation 2006 114: 753.[Full Text]
This article has been cited by other articles:
 |
|
 |
|
  A J Chase, E B Fretz, W P Warburton, W P Klinke, R G Carere, D Pi, B Berry, and J D Hilton Association of the arterial access site at angioplasty with transfusion and mortality: the M.O.R.T.A.L study (Mortality benefit Of Reduced Transfusion after percutaneous coronary intervention via the Arm or Leg) Heart, August 1, 2008; 94(8): 1019 - 1025. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Y. Chan, M. G. Cohen, C. K. Dyke, S. K. Myles, L. G. Aberle, M. Lin, J. Walder, S. R. Steinhubl, I. C. Gilchrist, N. S. Kleiman, et al. Phase 1b Randomized Study of Antidote-Controlled Modulation of Factor IXa Activity in Patients With Stable Coronary Artery Disease Circulation, June 3, 2008; 117(22): 2865 - 2874. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 W. Alvarez Jr. For better or for worse: The future of antiplatelet therapy Am. J. Health Syst. Pharm., June 1, 2008; 65(11): 1017 - 1017. [Full Text] [PDF]
|
|
|
|
 |
|
 J. D. Douketis, P. B. Berger, A. S. Dunn, A. K. Jaffer, A. C. Spyropoulos, R. C. Becker, and J. Ansell The Perioperative Management of Antithrombotic Therapy: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition) Chest, June 1, 2008; 133(6_suppl): 299S - 339S. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. A. Harrington, R. C. Becker, C. P. Cannon, D. Gutterman, A. M. Lincoff, J. J. Popma, G. Steg, G. H. Guyatt, and S. G. Goodman Antithrombotic Therapy for Non-ST-Segment Elevation Acute Coronary Syndromes: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition) Chest, June 1, 2008; 133(6_suppl): 670S - 707S. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. W. Stone, B. Witzenbichler, G. Guagliumi, J. Z. Peruga, B. R. Brodie, D. Dudek, R. Kornowski, F. Hartmann, B. J. Gersh, S. J. Pocock, et al. Bivalirudin during Primary PCI in Acute Myocardial Infarction N. Engl. J. Med., May 22, 2008; 358(21): 2218 - 2230. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. D. White, D. P. Chew, J. W. Hoekstra, C. D. Miller, C. V. Pollack Jr, F. Feit, A. M. Lincoff, M. Bertrand, S. Pocock, J. Ware, et al. Safety and efficacy of switching from either unfractionated heparin or enoxaparin to bivalirudin in patients with non-ST-segment elevation acute coronary syndromes managed with an invasive strategy: results from the ACUITY (Acute Catheterization and Urgent Intervention Triage strategY) trial. J. Am. Coll. Cardiol., May 6, 2008; 51(18): 1734 - 1741. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J.-P. Bassand Bleeding and transfusion in acute coronary syndromes: a shift in the paradigm Heart, May 1, 2008; 94(5): 661 - 666. [Full Text] [PDF]
|
|
|
|
 |
|
 J.-P. Bassand Unmet needs in antiplatelet therapy Eur. Heart J. Suppl., May 1, 2008; 10(suppl_D): D3 - D11. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Levi, G. K. Hovingh, S. C. Cannegieter, M. Vermeulen, H. R. Buller, and F. R. Rosendaal Bleeding in patients receiving vitamin K antagonists who would have been excluded from trials on which the indication for anticoagulation was based Blood, May 1, 2008; 111(9): 4471 - 4476. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. Feit, S. V. Manoukian, R. Ebrahimi, C. V. Pollack, E. M. Ohman, M. J. Attubato, R. Mehran, and G. W. Stone Safety and Efficacy of Bivalirudin Monotherapy in Patients With Diabetes Mellitus and Acute Coronary Syndromes: A Report From the ACUITY (Acute Catheterization and Urgent Intervention Triage Strategy) Trial J. Am. Coll. Cardiol., April 29, 2008; 51(17): 1645 - 1652. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. A. Henriksen, K. Palmer, and N. A. Boon Management of upper gastrointestinal haemorrhage complicating dual anti-platelet therapy QJM, April 1, 2008; 101(4): 261 - 267. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J.-P. Bassand The place of fondaparinux in the ESC and ACC/AHA guidelines for anticoagulation in patients with non-ST elevation acute coronary syndromes Eur. Heart J. Suppl., April 1, 2008; 10(suppl_C): C22 - C29. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F. A. Spencer, J. M. Gore, D. Lessard, J. D. Douketis, C. Emery, and R. J. Goldberg Patient Outcomes After Deep Vein Thrombosis and Pulmonary Embolism: The Worcester Venous Thromboembolism Study Arch Intern Med, February 25, 2008; 168(4): 425 - 430. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. Ndrepepa, P. B. Berger, J. Mehilli, M. Seyfarth, F.-J. Neumann, A. Schomig, and A. Kastrati Periprocedural Bleeding and 1-Year Outcome After Percutaneous Coronary Interventions Appropriateness of Including Bleeding as a Component of a Quadruple End Point. J. Am. Coll. Cardiol., February 19, 2008; 51(7): 690 - 697. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. L. Dauerman Percutaneous Coronary Intervention Pharmacology From a Triangle to a Square. J. Am. Coll. Cardiol., February 19, 2008; 51(7): 698 - 700. [Full Text] [PDF]
|
|
|
|
 |
|
 J. Oldgren, L. Wallentin, R. Afzal, J.-P. Bassand, A. Budaj, S. Chrolavicius, K. A.A. Fox, C. B. Granger, S. R. Mehta, P. Pais, et al. Effects of fondaparinux in patients with ST-segment elevation acute myocardial infarction not receiving reperfusion treatment Eur. Heart J., February 1, 2008; 29(3): 315 - 323. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. A. Spencer, M. Moscucci, C. B. Granger, J. M. Gore, R. J. Goldberg, P. G. Steg, S. G. Goodman, A. Budaj, G. FitzGerald, K. A.A. Fox, et al. Does Comorbidity Account for the Excess Mortality in Patients With Major Bleeding in Acute Myocardial Infarction? Circulation, December 11, 2007; 116(24): 2793 - 2801. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. W. Stone, J. H. Ware, M. E. Bertrand, A. M. Lincoff, J. W. Moses, E. M. Ohman, H. D. White, F. Feit, A. Colombo, B. T. McLaurin, et al. Antithrombotic Strategies in Patients With Acute Coronary Syndromes Undergoing Early Invasive Management: One-Year Results From the ACUITY Trial JAMA, December 5, 2007; 298(21): 2497 - 2506. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. R. Mehta, C. B. Granger, J. W. Eikelboom, J.-P. Bassand, L. Wallentin, D. P. Faxon, R. J.G. Peters, A. Budaj, R. Afzal, S. Chrolavicius, et al. Efficacy and Safety of Fondaparinux Versus Enoxaparin in Patients With Acute Coronary Syndromes Undergoing Percutaneous Coronary Intervention: Results From the OASIS-5 Trial J. Am. Coll. Cardiol., October 30, 2007; 50(18): 1742 - 1751. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. P. Giugliano and E. Braunwald The Year in Non ST-Segment Elevation Acute Coronary Syndrome J. Am. Coll. Cardiol., October 2, 2007; 50(14): 1386 - 1395. [Full Text] [PDF]
|
|
|
|
|
|
J. L. Anderson, C. D. Adams, E. M. Antman, C. R. Bridges, R. M. Califf, D. E. Casey Jr, W. E. Chavey II, F. M. Fesmire, J. S. Hochman, T. N. Levin, et al. ACC/AHA 2007 Guidelines for the Management of Patients With Unstable Angina/Non-ST-Elevation Myocardial Infarction: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines for the Management of Patients With Unstable Angina/Non-ST-Elevation Myocardial Infarction) Developed in Collaboration with the American College of Emergency Physicians, the Society for Cardiovascular Angiography and Interventions, and the Society of Thoracic Surgeons Endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation and the Society for Academic Emergency Medicine J. Am. Coll. Cardiol., August 14, 2007; 50(7): e1 - e157. [Full Text] [PDF]
|
|
|
|
|
|
N. M. A. LaPointe, A. Y. Chen, K. P. Alexander, M. T. Roe, C. V. Pollack Jr, B. L. Lytle, M. E. Ohman, B. W. Gibler, and E. D. Peterson Enoxaparin Dosing and Associated Risk of In-Hospital Bleeding and Death in Patients With Non ST-Segment Elevation Acute Coronary Syndromes Arch Intern Med, July 23, 2007; 167(14): 1539 - 1544. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. R. Dixon, C. L. Grines, and W. W. O'Neill The Year in Interventional Cardiology J. Am. Coll. Cardiol., July 17, 2007; 50(3): 270 - 285. [Full Text] [PDF]
|
|
|
|
|
|
D. J. Schneider and B. E. Sobel Conundrums in the Combined Use of Anticoagulants and Antiplatelet Drugs Circulation, July 17, 2007; 116(3): 305 - 315. [Full Text] [PDF]
|
|
|
|
|
|
Authors/Task Force Members, J.-P. Bassand, C. W. Hamm, D. Ardissino, E. Boersma, A. Budaj, F. Fernandez-Aviles, K. A.A. Fox, D. Hasdai, E. M. Ohman, et al. Guidelines for the diagnosis and treatment of non-ST-segment elevation acute coronary syndromes: The Task Force for the Diagnosis and Treatment of Non-ST-Segment Elevation Acute Coronary Syndromes of the European Society of Cardiology Eur. Heart J., July 1, 2007; 28(13): 1598 - 1660. [Full Text] [PDF]
|
|
|
|
|
|
J.-P. Bassand Impact of anaemia, bleeding, and transfusions in acute coronary syndromes: a shift in the paradigm Eur. Heart J., June 1, 2007; 28(11): 1273 - 1274. [Full Text] [PDF]
|
|
|
|
|
|
S. V. Rao, J. A. Eikelboom, C. B. Granger, R. A. Harrington, R. M. Califf, and J.-P. Bassand Bleeding and blood transfusion issues in patients with non-ST-segment elevation acute coronary syndromes Eur. Heart J., May 2, 2007; 28(10): 1193 - 1204. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. V. Manoukian, F. Feit, R. Mehran, M. D. Voeltz, R. Ebrahimi, M. Hamon, G. D. Dangas, A. M. Lincoff, H. D. White, J. W. Moses, et al. Impact of Major Bleeding on 30-Day Mortality and Clinical Outcomes in Patients With Acute Coronary Syndromes: An Analysis From the ACUITY Trial J. Am. Coll. Cardiol., March 27, 2007; 49(12): 1362 - 1368. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. K. Dyke, S. R. Steinhubl, N. S. Kleiman, R. O. Cannon, L. G. Aberle, M. Lin, S. K. Myles, C. Melloni, R. A. Harrington, J. H. Alexander, et al. First-in-Human Experience of an Antidote-Controlled Anticoagulant Using RNA Aptamer Technology: A Phase 1a Pharmacodynamic Evaluation of a Drug-Antidote Pair for the Controlled Regulation of Factor IXa Activity Circulation, December 5, 2006; 114(23): 2490 - 2497. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. W. Mahaffey and R. C. Becker The Scientific Community's Quest to Identify Optimal Targets for Anticoagulant Pharmacotherapy Circulation, November 28, 2006; 114(22): 2313 - 2316. [Full Text] [PDF]
|
|
|
|
 |
|
 Major Bleeding After ACS Predicts Mortality Journal Watch Cardiology, October 11, 2006; 2006(1011): 4 - 4. [Full Text]
|
|